Skip to main content

You are here

PTCommunity News October 2005

Abciximab Trial for Acute Ischemic Stroke Halted Permanently
Clobetasol Propionate Spray Approved for Moderate-to-Severe Plaque Psoriasis
FDA Grants Fast Track Designation to AT-1001, First Clinical Study Completed
Study Reveals $20 Billion in Untapped Generic Drug Savings
Rituximab Gains Priority Review Status for Previously Untreated Patients With Non-Hodgkin's Lymphoma
Approvable Letter Issued for Modafinil in Children, Adolescents With Attention-Deficit/Hyperactivity Disorder
Phase 3 Data Demonstrate Single Intravitreous Injection of Vitrase Results in Improved Visual Acuity
Patient Enrollment Goal Achived in Phase 3 Trial of Toremifene, Treatment for Androgen Deprivation Therapy
Phase 3 Trial of Pegaptanib in Diabetic Macular Edema and Diabetic Retinopathy Initiated
Positive Results Reported for Phase 2 Study of Tadalafil in Treating Symptoms of Benign Prostatic Hyperplasia
Preliminary Phase 2 Data Shows Squalamine With Visudyne Demonstrate Safety in Macular Degeneration Patients
Stroke Patients With Mild Symptoms May Still Need Clot-Dissolving Drug
Phase 3 Trial Initiated To Evaluate Tobramycin Inhalation Powder in Cystic Fibrosis Patients
Adalimumab Approved To Reduce Signs, Symptoms of Psoriatic Arthritis
Adalimumab Gains Indication for First-Line Treatment of Moderate to Severe Rheumatoid Arthritis